Immucor, Inc. hit by Shareholder lawsuit

PRLog (Press Release) - Sep 03, 2009 -
An investor in Immucor, Inc. (Public, NASDAQ:BLUD)  has filed a lawsuit in the United States District Court for the Northern District of Georgia on behalf of purchasers of Immucor, Inc. (NASDAQ:BLUD) publicly traded securities during the period between October 19, 2005 and April 23, 2009, against Immucor and others over alleged violations of Federal Securities Laws.

If you purchased Immucor, Inc. (NASDAQ:BLUD) publicly traded securities during the period between October 19, 2005 and April 23, 2009, you have certain options and there are strict and short deadlines running. Deadline: October 23, 2009. Those BLUD investors and current long term investors should contact the Shareholders Foundation, Inc. at:

Email: mail@shareholdersfoundation.com

Or call us at: +1 (858) 779 - 1554

According to the complaint the plaintiff alleges that Immucor and certain of its officers and directors violated the Securities Exchange Act of 1934 by failing to disclose that Immucor was operating in violation of the federal antitrust laws of the United States.  The plaintiff accuses that between October 19, 2005 and April 23, 2009 the defendants materially misrepresented Immucor’s business operations. On April 24, 2009, Immucor issued a press release, which stated in part: “Immucor, Inc., a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that it received a subpoena from the United States Department of Justice, Antitrust Division, requesting documents for the period beginning September 1, 2000 through the present, pertaining to an investigation of possible violations of the federal criminal antitrust laws in the blood reagents industry. Immucor intends to fully cooperate with the investigation.”
As a result of this disclosure, Immucor’s closing stock price dropped from $20.98 on April 23, 2009 to $15.35 the next trading day, so the lawsuit.
The plaintiff accuses that this decrease in Immucor’s stock price was a result of the artificial inflation caused by defendants’ misleading statements coming out of the stock price.
Immucor, Inc, located in Norcross, GA, develops, manufactures and sells a line of reagents and automated systems that detect and identify certain properties of the cell and serum components of human blood for the purpose of blood transfusion. Immucor, Inc reported in 2007 (ending on May 31, 2008) Total Revenue of 261.20million with a Net Income of $71.45million and in 2008 (ending on May 31, 2009) Total Revenue of $300.55million with a Net Income of $76.18million. Immucor, Inc shares (NASDAQ: BLUD) recently traded at $18.47 per share, down from a 52weekHigh of $33.80 per share and almost $40 per share in 2007.

Those who purchased Immucor, Inc. (NASDAQ:BLUD) publicly traded securities during the period between October 19, 2005 and April 23, 2009, have certain options and there are strict and short deadlines running. Deadline: October 23, 2009. Those BLUD investors and current long term investors should contact the Shareholders Foundation, Inc. at:

Email: mail@shareholdersfoundation.com

Or call us at: +1 (858) 779 - 1554

Shareholders Foundation, Inc.
Trevor Allen
3111 Camino Del Rio North - Suite 423 -
92108 San Diego
Tel:+1-(858)-779-1554
Fax:+1-(858)-605-5739
mail@shareholdersfoundation.com
www.ShareholdersFoundation.com
_____________________________________________________________________________________